Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rafael Holdings ( (RFL) ) has issued an announcement.
On April 22, 2026, Rafael Holdings said its subsidiary Cyclo Therapeutics signed an exclusive license with MIT for a U.S. patent covering the use of cyclodextrins in treating Alzheimer’s patients who carry the ApoE4 mutation. The deal expands protection around Trappsol® Cyclo™ in an ApoE4-positive population, where dysregulated cholesterol metabolism is thought to drive amyloid and tau pathology.
Rafael highlighted preclinical data indicating Trappsol® Cyclo™ can improve cholesterol transport between central nervous system cells, reduce tau pathology and enhance learning and memory in mice, potentially targeting underlying disease mechanisms. Executives framed the license as a transformative milestone that strengthens the company’s Alzheimer’s program while it awaits Phase 3 results in Q3 2026 from Transport NPC, the largest study conducted in Niemann-Pick Type C1, which could further shape Trappsol® Cyclo™’s role across multiple indications.
Spark’s Take on RFL Stock
According to Spark, TipRanks’ AI Analyst, RFL is a Neutral.
The score is primarily held back by weak financial performance driven by large ongoing losses and cash burn, partially offset by low leverage. Technical indicators are mixed/neutral, and valuation is not supportive given negative earnings and no dividend data.
To see Spark’s full report on RFL stock, click here.
More about Rafael Holdings
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies focused on drugs and medical devices. Its lead candidate, Trappsol® Cyclo™, is being evaluated in a pivotal Phase 3 clinical trial for the treatment of Niemann-Pick Disease Type C1, a rare, fatal and progressive genetic disorder.
The company also maintains stakes in other clinical-stage and early-stage pharmaceutical developers as well as an orthopedic-focused medical device firm, reflecting a diversified portfolio in life sciences. Rafael’s strategy centers on advancing Trappsol® Cyclo™ while leveraging its broader holdings to participate in multiple therapeutic areas and technologies.
Average Trading Volume: 76,510
Technical Sentiment Signal: Sell
Current Market Cap: $64.51M
For detailed information about RFL stock, go to TipRanks’ Stock Analysis page.